RegenLab Issued New US Patent for Platelet Rich Plasma Kits

RegenLab is attempting to enforce its patent rights against Estar Technologies Ltd., manufacturer of
the Eclipse PRP product, Eclipse Aesthetics LLC, a US distributor, as well as their customers.

New York, NY, December 05, 2017 --(PR.com)-- On December 5, 2017, RegenLab USA LLC
(RegenLab) alleges to have obtained US Pat. No. 9,833,478 (the '478 patent), with claims directed to
medical separator systems for the preparation of platelet rich plasma.

Since November 2016, RegenLab has been involved in patent litigation with Israeli manufacturer Estar
Technologies Ltd. (Estar) and US distributor Eclipse Aesthetics LLC (Eclipse) over the importation
and distribution of a product called Eclipse PRP. Case No. 16-cv-08771 (ALC) (S.D.N.Y.) (filed Nov.
11, 2016). In the case, RegenLab alleged that Estar marketed this product under various other brand
names, including Healeon PRP, Tropocells, Mycells, and Cellenis. RegenLab has alleged that Estar and
Eclipse willfully copied RegenLab's technology, despite having known about RegenLab's patent rights for
many years. RegenLab has further alleged that Estar and Eclipse knowingly and deliberately induced
customers to infringe RegenLab's patents through the promotion, use, resale, and offer for sale of the
Eclipse PRP product.

However, Estar and Eclipse have filed motions to dismiss, allegedly to avoid liability. In its motion, Estar
alleges that it is not subject to personal jurisdiction in New York and that it has no customers" there. For
its part, Eclipse alleges in its motion that it can only be sued in Texas, despite allegedly having a network
of salespeople throughout the US. In order to address the alleged ongoing infringement related to the
Eclipse PRP product, RegenLab filed suit against Estar and Eclipse's customers, Case No. 1:17-cv-03845
(ALC) (S.D.N.Y.) (filed May 22, 2017). In this case, RegenLab has alleged that the customers have their
own liability and are not indemnified by Estar and Eclipse.

To date, RegenLab's allegations have concerned infringement of US Pat. No. 8,529,957 (the '957
patent). Asserted claim 20 of the '957 patent is a method claim requiring the admixture of cell extracts to
platelet rich plasma. Allegedly, users of the Eclipse PRP product can directly infringe claim 20 of the '957
patent by mixing the platelet rich plasma with cell extracts. In an alleged attempt to avoid infringement,
Estar and Eclipse filed court documents with customer affidavits attesting to the purchase and use of the
Eclipse PRP product, but that denied performing the claimed mixing step. Now, however, RegenLab is
alleging that claims of the '478 patent cover the Eclipse PRP product itself and that RegenLab will argue
in its court documents that infringement of the '478 patent is supported by the very affidavits drafted by
Estar and Eclipse.

With the '478 patent, RegenLab states it will continue to enforce its patent rights against distributors and
customers for infringing promotion, sale, and use of the Eclipse PRP product. New defendants may be
added to lawsuits as they are identified and RegenLab may seek treble damages resulting from the use
and sale of the Eclipse PRP product, attorneys' fees and costs, and a permanent injunction to preclude
continued infringement.

Page 1/3
PR.com Press Release Distribution Terms of Use
RegenLab is a leading innovator of medical products for the preparation of platelet rich plasma, which it
markets under the world-famous REGENLAB brand. RegenLab's products for preparing platelet rich
plasma include its RegenKit products. Over the course of many years, RegenLab has developed a
substantial patent portfolio, which it is enforcing against accused infringers around the world. RegenLab's
patent portfolio includes numerous continuation and divisional applications related to the '957 and '478
patents. RegenLab remains committed to providing products of the highest quality and safety, as well as
protecting customers through enforcement of its intellectual property rights.

Additional information about RegenLab can be found at www.RegenLabUSA.com.

Page 2/3
PR.com Press Release Distribution Terms of Use
Contact Information:
RegenLab USA LLC
John J. Pezzillo
1-800-220-9082
Contact via Email
www.regenlabusa.com

Online Version of Press Release:

You can read the online version of this press release at: https://www.pr.com/press-release/737774

News Image:

Page 3/3
PR.com Press Release Distribution Terms of Use